
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is poised for future revenue growth due to its TRACER platform, which is advancing collaborations toward clinical trials expected in the 2030s. The company demonstrated promising preclinical results, such as VY1706 achieving significant reductions in tau messenger RNA and protein levels in non-human primates, with a favorable safety profile compared to existing AAV delivery methods. Additionally, data from the NeuroShuttle platform indicates enhanced central nervous system exposure duration, further establishing Voyager's competitive edge in gene therapy for neurological diseases.
Bears say
Voyager Therapeutics Inc faces a challenging financial outlook due to a combination of limited cash reserves, which may hinder its ability to fund ongoing clinical trials and research endeavors. Additionally, the company's reliance on a narrow pipeline centered around AAV-based gene therapies raises concerns about the potential for delayed or unsuccessful product development, impacting future revenue streams. Lastly, increasing competition within the gene therapy sector could further strain Voyager's market position, contributing to a negative sentiment surrounding its stock performance.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares